Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-139981

Published: 2020

Journal Articles

Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-143082

Published: 2020

Journal Articles

Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting

Jacopo Nanni, MD, Cristina Papayannidis, MD PhD, Gianluca Cristiano, MD, Giovanni Marconi, MD, Chiara Sartor, MD, Sarah Parisi, MDPhD, Emanuela Ottaviani, Lorenza Baldini, MSc, Nicoletta Testoni, Carmen Baldazzi, PhD, Paolo Ricci, MD, Chiara Di Giovanni Bezzi, MD, Rania Abd-alatif, MD, Stefania Paolini, MD PhD, Michele Cavo, Antonio Curti, MDPhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-138719

Published: 2020

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians. Further Clues Linking Chip with Cardiovascular Risk

Luca Bertamini, MD, Claudia Sala, Nicola Martinelli, MD PhD, Cristina Papayannidis, MD PhD, Cristina Giuliani, Giovanni Malerba, Paolo Garagnani, Oliviero Olivieri, Giovanni Martinelli, MD, Claudio Franceschi, Domenico Girelli, MD PhD

Blood (2017) 130 (Supplement 1): 1144.

https://doi.org/10.1182/blood.V130.Suppl_1.1144.1144

Published: 2017

Journal Articles

First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 99.

https://doi.org/10.1182/blood.V130.Suppl_1.99.99

Published: 2017

Journal Articles

Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations

Giorgia Simonetti, PhD, Samantha Bruno, MSc, Carmine Onofrillo, PhD, Marco Malferrari, PhD, Cristina Papayannidis, MD PhD, Giovanni Marconi, MD, Michele Cavo, MD, Stefania Rapino, PhD, Lorenzo Montanaro, MD PhD, Giovanni Martinelli, MD

Blood (2017) 130 (Supplement 1): 3936.

https://doi.org/10.1182/blood.V130.Suppl_1.3936.3936

Published: 2017

Journal Articles

Hypometilating Agents (HMA) As Salvage Therapy in Relapsed or Refractory AML: A 5-Center Retrospective Study

Marica Laurino, MD, Federica Lessi, MD, Antonio Branca, MD, Silvia Imbergamo, MD, Elena Crisà, Anna Candoni, MD, Davide Lazzarotto, MD, Michele Gottardi, MD, Cristina Papayannidis, MD PhD, Gianpietro Semenzato, MD

Blood (2017) 130 (Supplement 1): 5051.

https://doi.org/10.1182/blood.V130.Suppl_1.5051.5051

Published: 2017

Journal Articles

Mine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs

Andrea Ghelli Luserna di Rorà, Ilaria Iacobucci, PhD, Neil Beeharry, Maria Vittoria Falzacappa, Chiara Ronchini, Cristina Papayannidis, MD PhD, Enrica Imbrogno, Anna Ferrari, PhD, Valentina Robustelli, Antonella Padella, Giovanni Martinelli, Timothy Yen

Blood (2016) 128 (22): 2808.

https://doi.org/10.1182/blood.V128.22.2808.2808

Published: 2016

Journal Articles

Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform

Laura Rocchi, PhD, Andrea Faenza, PhD, Laura Rambelli, Viviana Guadagnuolo, PhD, Giovanni Marconi, MD, Giorgia Simonetti, PhD, Cristina Papayannidis, MD PhD, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, MD PhD, Roberto Guerrieri, PhD, Massimo Bocchi, PhD

Blood (2016) 128 (22): 1675.

https://doi.org/10.1182/blood.V128.22.1675.1675

Published: 2016

Journal Articles

Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis

Blood (2016) 128 (22): 1677.

https://doi.org/10.1182/blood.V128.22.1677.1677

Published: 2016

Journal Articles

Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations

Blood (2016) 128 (22): 1678.

https://doi.org/10.1182/blood.V128.22.1678.1678

Published: 2016

Journal Articles

Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 1679.

https://doi.org/10.1182/blood.V128.22.1679.1679

Published: 2016

Journal Articles

Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50

Blood (2016) 128 (22): 1702.

https://doi.org/10.1182/blood.V128.22.1702.1702

Published: 2016

Journal Articles

Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience

Blood (2016) 128 (22): 5191.

https://doi.org/10.1182/blood.V128.22.5191.5191

Published: 2016

Journal Articles

The Genomic and Transcriptomic Landscape of Systemic Mastocytosis

Blood (2016) 128 (22): 3136.

https://doi.org/10.1182/blood.V128.22.3136.3136

Published: 2016

Journal Articles

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Simona Soverini, Caterina De Benedittis, Stefania Stella, Anna Serra, Francesca Carnuccio, Santa Errichiello, PhD, Luana Bavaro, Fausto Castagnetti, MD, Alessandra Iurlo, MD, Nicola Orofino, MD, Federica Sorà, Simona Sica, Sara Galimberti, MD PhD, Claudia Baratè, Federica Mottadelli, Margherita Martelli, Elisabetta Novella, Eros Di Bona, MD, Giorgina Specchia, Francesco Albano, Elisabetta Abruzzese, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Carmen Fava, MD, Giovanna Rege Cambrin, MD, Luigia Luciano, Massimo Breccia, MD, Clementina Caracciolo, MD, Marco Santoro, Francesco Di Raimondo, MD, Gabriele Gugliotta, Cristina Papayannidis, MD PhD, Giovanni Cazzaniga, Manuela Mancini, Rosaria Sancetta, Renato Bassan, Caterina Musolino, MD, Giuseppina Spinosa, Silvana Franca Capalbo, Mario Annunziata, MD, Michele Cavo, MD, Gianantonio Rosti, Michele Baccarani, Paolo Vigneri, Giuseppe Saglio, MD, Fabrizio Pane, Giovanni Martinelli

Blood (2016) 128 (22): 3097.

https://doi.org/10.1182/blood.V128.22.3097.3097

Published: 2016

Journal Articles

Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2015) 126 (23): 2513.

https://doi.org/10.1182/blood.V126.23.2513.2513

Published: 2015

Journal Articles

The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia

Andrea Ghelli Luserna Di Rora, Ilaria Iacobucci, PhD, Enrica Imbrogno, Enrico Derenzini, MD, Anna Ferrari, PhD, Viviana Guadagnuolo, PhD, Valentina Robustelli, Simona Soverini, Cristina Papayannidis, MD PhD, Maria Chiara Abbenante, MD, Michele Cavo, MD, Giovanni Martinelli, MD PhD

Blood (2015) 126 (23): 2478.

https://doi.org/10.1182/blood.V126.23.2478.2478

Published: 2015

Journal Articles

Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia

Blood (2015) 126 (23): 2600.

https://doi.org/10.1182/blood.V126.23.2600.2600

Published: 2015

Journal Articles

Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters

Simona Soverini, PhD, Caterina De Benedittis, PhD, Claudia Venturi, PhD, Cristina Papayannidis, MD PhD, Manuela Mancini, PhD, Katerina Machova Polakova, Domenico Russo, MD PhD, Paola Bresciani, MD, Alessandra Iurlo, MD PhD, Elisabetta Abruzzese, MD, Federica Sorà, MD PhD, Michele Baccarani, Michele Cavo, MD, Torsten Haferlach, Giovanni Martinelli, MD PhD

Blood (2015) 126 (23): 2489.

https://doi.org/10.1182/blood.V126.23.2489.2489

Published: 2015

NARROW

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients

Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting

Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians. Further Clues Linking Chip with Cardiovascular Risk

First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations

Hypometilating Agents (HMA) As Salvage Therapy in Relapsed or Refractory AML: A 5-Center Retrospective Study

Mine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs

Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform

Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis

Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations

Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)

Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50

Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience

The Genomic and Transcriptomic Landscape of Systemic Mastocytosis

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia

The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia

Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia

Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only